Unique Genomic Alterations in the Circulating Tumor DNA of Patients With Solid Tumors Brain Metastases

While serum circulating tumor DNA (ctDNA) is routine, data from patients with brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA from patients with solid tumor BrMs in three groups: isolated BrMs with stable extracranial disease (iCNS), concurrent brain and extracranial progression (cCNS), and extracranial progression with no active BrMs (eCNS). We also compared ctDNA alterations between patients with and without BrMs. Patients with a Guardant360 ctDNA profile with (n=253) and without BrMs (n=449) from the Duke Molecular Registry between 01/2014 – 12/2020 were identified. Actionable alterations were defined as FDA-recognized or standard of care biomarkers. Disease status was determined via investigator assessment within 30 days of ctDNA collection. Among the 253 patients with BrMs: 29 (12%) had iCNS, 160 (63%) cCNS, and 64 (25%) eCNS. Breast (BC) (12.0%) and non-small cell lung cancer (NSCLC) (76.4%) were the most common tumor types. ESR1 (60% vs 25%, p< 0.001) and BRCA2 (17% vs 5%, p=0.022) were more frequent in BC BrMs. In NSCLC BrMs, EGFR alterations were most frequent in the iCNS group (iCNS: 67%, cCNS: 40%, eCNS:37%, p=0.08 and in patients with BrMs (36% vs 17%, p<0.001). Sequencing from both brain tissue and ctDNA were available for 8 patients; 7 (87.5%) had identical alterations. This study illustrates the feasibility of detecting alterations from ctDNA among patients with BrMs. A higher frequency of actionable mutations was observed in ctDNA in patients with BrMs. Additional studies comparing ctDNA and alterations in BrMs tissue are needed to determine if ctDNA can be considered a surrogate to support treatment decisions.